Department of Epidemiology, Division of Epidemiology and Disease Control, University of Texas School of Public Health.
Department of Epidemiology, Division of Epidemiology and Disease Control, University of Texas School of Public Health.
Ann Oncol. 2010 Sep;21(9):1825-1833. doi: 10.1093/annonc/mdq042. Epub 2010 Mar 8.
The study's objective was to investigate the risks of developing cardiac disorders following the administration of chemotherapy and radiation therapy in patients with non-small-cell lung cancer (NSCLC).
The study consisted of 34 209 patients aged > or =65 years with American Joint Committee on Cancer stages I-IV NSCLC identified from the Surveillance, Epidemiology, and End Result-Medicare linked database (1991-2002) who were free of cardiac disorders at NSCLC diagnosis.
There were significant associations between the use of chemotherapy/radiation and the risks of developing ischemic heart disease, conduction disorders, cardiac dysfunction, and heart failure. The absolute risks for cardiac dysfunction increased with the administration of chemotherapy-only and radiation-only, and incrementally with chemoradiation. Men, blacks, older patients, those with higher comorbidity scores, and advanced disease were at higher risk. The risk for ischemic heart disease increased when radiation/chemoradiation were rendered to the left lung and both lungs and for cardiac dysfunction, radiation administered to the left lung.
There were significant associations especially for cardiac dysfunction with use of chemotherapy/radiation therapy and risks of developing cardiac toxicity in NSCLC patients. The risks of treatment-associated cardiac toxicity, specifically ischemic heart disease and cardiac dysfunction, were greatest among those with left-sided lung tumors.
本研究旨在探讨非小细胞肺癌(NSCLC)患者接受化疗和放疗后发生心脏疾病的风险。
该研究纳入了 34209 例年龄≥65 岁的美国癌症联合委员会(AJCC)分期 I-IV 期 NSCLC 患者,这些患者来自监测、流行病学和最终结果-医疗保险链接数据库(1991-2002 年),在 NSCLC 确诊时无心脏疾病。
化疗/放疗的应用与发生缺血性心脏病、传导障碍、心功能障碍和心力衰竭的风险之间存在显著相关性。仅化疗和仅放疗的应用与心功能障碍的绝对风险增加有关,并随着放化疗的应用而递增。男性、黑人、老年患者、合并症评分较高者和晚期疾病患者的风险更高。当放疗/放化疗应用于左肺和双肺时,缺血性心脏病的风险增加,而当左肺接受放疗时,心功能障碍的风险增加。
尤其是化疗/放疗的应用与 NSCLC 患者发生心脏毒性的风险之间存在显著相关性,特别是与缺血性心脏病和心功能障碍相关。在左肺肿瘤患者中,治疗相关心脏毒性(特别是缺血性心脏病和心功能障碍)的风险最大。